0001493152-24-009224.txt : 20240307 0001493152-24-009224.hdr.sgml : 20240307 20240307164708 ACCESSION NUMBER: 0001493152-24-009224 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240305 ITEM INFORMATION: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant ITEM INFORMATION: Other Events FILED AS OF DATE: 20240307 DATE AS OF CHANGE: 20240307 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AgeX Therapeutics, Inc. CENTRAL INDEX KEY: 0001708599 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 821436829 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38519 FILM NUMBER: 24730889 BUSINESS ADDRESS: STREET 1: 1101 MARINA VILLAGE PARKWAY STREET 2: SUITE 201 CITY: ALAMEDA STATE: CA ZIP: 94501 BUSINESS PHONE: 510-671-8370 MAIL ADDRESS: STREET 1: 1101 MARINA VILLAGE PARKWAY STREET 2: SUITE 201 CITY: ALAMEDA STATE: CA ZIP: 94501 8-K 1 form8-k.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): March 5, 2024

AgeX Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware		1-38519		82-1436829
(State or other jurisdiction		(Commission		(IRS Employer
of incorporation)		File Number)		Identification No.)

1101 Marina Village Parkway

Suite 201

Alameda, California 94501

(Address of principal executive offices)

(510) 671-8370

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol		Name of exchange on which registered
Common Stock, par value $0.0001 per share		AGE		NYSE American

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☒	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

On March 5, 2024, AgeX Therapeutics, Inc., a Delaware corporation (“AgeX”), drew $500,000 of its credit available under the Amended and Restated Secured Convertible Promissory Note, as amended ( the “Secured Note”), with Juvenescence Limited.

The Repayment Date on which the outstanding principal balance of the Secured Note will become due and payable shall be May 9, 2024. The other material terms of the Secured Note are summarized in AgeX’s Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission (the “SEC”) on November 14, 2023.

Item 8.01 – Other Events.

As previously announced, on August 29, 2023, AgeX entered into an Agreement and Plan of Merger and Reorganization (the “Merger Agreement”) with Serina Therapeutics Inc., an Alabama corporation (“Serina”), and Canaria Transaction Corporation, an Alabama corporation and wholly owned subsidiary of AgeX (“Merger Sub”), pursuant to which, among other matters and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Merger Sub will merge with and into Serina, with Serina surviving as a wholly owned subsidiary of AgeX (the “Merger”), as more fully described in AgeX’s definitive proxy statement/prospectus/information statement filed with the SEC on February 14, 2024 (the “Proxy Statement/Prospectus/Information Statement”), a copy of which was first mailed to AgeX stockholders on or about February 20, 2024.

On March 7, 2024, the Board of Directors of AgeX (the “AgeX Board”) declared a warrant dividend (the “Warrant Dividend”) in connection with the Merger that is expected to be issued on or about March 19, 2024 to all stockholders of record as of the close of business on March 18, 2024 (the “Warrant Dividend Record Date”), subject to, among other things, obtaining stockholder approval of the Warrant Dividend and a proposed reverse stock split (the “Reverse Stock Split”) at the Special Meeting (as defined below) and the Reverse Stock Split being effected prior the Warrant Dividend Record Date, as more fully described in the Proxy Statement/Prospectus/Information Statement. Assuming, among other things, that AgeX receives stockholder approval for the Reverse Stock Split, it is anticipated the Reverse Stock Split will be effected on March 14, 2024 with shares of AgeX common stock to commence trading on a post-Reverse Stock Split basis effective with the open of business on March 15, 2024.

The Warrant Dividend will consist of three warrants (each, a “Post-Merger Warrant”) for each five shares of AgeX common stock issued and outstanding held by the stockholder of record as of the Warrant Dividend Record Date. Each Post-Merger Warrant will be exercisable at an exercise price equal to $13.20 per warrant (such exercise price reflecting the Reverse Stock Split) for (i) one share of AgeX common stock and (ii) one warrant (each, an “Incentive Warrant”) and will expire on July 31, 2025. Each Incentive Warrant will be exercisable at an exercise price equal to $18.00 per warrant (such exercise price reflecting the Reverse Stock Split) for one share of AgeX common stock and will expire on the four-year anniversary of closing of the Merger. Each Post-Merger Warrant and Incentive Warrant will be issued pursuant to the terms of a warrant agreement to be entered into by AgeX and a warrant agent in connection with the closing of the Merger. No fractional warrants will be issued. The number of Post-Merger Warrants to be issued to a stockholder of record will be rounded down to the nearest whole number if such holder would be entitled to receive a fractional warrant. For additional information regarding the Warrant Dividend and the terms of the Post-Merger Warrant and Incentive Warrant, please refer to the Proxy Statement/Prospectus/Information Statement.

AgeX will hold a special meeting of stockholders (the “Special Meeting”) on March 14, 2024, unless postponed or adjourned to a later date, for the purpose of voting on the proposals contained in the Proxy Statement/Prospectus/Information Statement, including the proposals pertaining to the Warrant Dividend and the Reverse Stock Split. The distribution of the Warrant Dividend is contingent on, among other things, obtaining approval of AgeX’s stockholders at the Special Meeting and the Reverse Stock Split being effected prior to the Warrant Dividend Record. The Reverse Stock Split is contingent on, among other things, obtaining approval of AgeX’s stockholders at the Special Meeting. To the extent that the effectiveness of the Reverse Stock Split and the commencement of shares of AgeX common stock trading on a post-Reverse Stock Split basis is delayed or postponed, the Warrant Dividend Record Date and the Warrant Dividend will be correspondingly delayed or postponed.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements contained in this communication regarding matters that are not historical facts are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, known as the PSLRA. These include statements regarding the anticipated completion and effects of the proposed Merger and related timing, including the anticipated completion and timing of the Warrant Dividend, Warrant Dividend Record Date and the Reverse Stock Split, pro forma descriptions of the combined company, Serina’s and the combined company’s planned preclinical and clinical programs, including planned clinical trials, the potential of Serina’s product candidates, the anticipated cash expected from warrant exercises and the ability for proceeds to fund the operations of the combined company for as long as anticipated, the expected trading of the combined company’s stock on the NYSE American under the ticker symbol “SER”, management of the combined company and other statements regarding management’s intentions, plans, beliefs, expectations or forecasts for the future. All forward-looking statements are based on assumptions or judgments about future events and economic conditions that may or may not be correct or necessarily take place and that are by their nature subject to significant risks, uncertainties and contingencies. You are cautioned not to place undue reliance on these forward-looking statements. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Statements that contain words such as “anticipates,” “believes,” “plans,” “expects,” “projects,” “future,” “intends,” “may,” “will,” “should,” “could,” “estimates,” “predicts,” “potential,” “continue,” “guidance,” and similar expressions to identify these forward-looking statements that are intended to be covered by the safe-harbor provisions of the PSLRA.

There are a number of risks and uncertainties that could cause actual results to differ materially from the forward-looking statements included in this communication. With respect to the Merger, these risks and uncertainties include: the possibility that stockholders of AgeX may not approve the Merger; one or more conditions to consummating the Merger may not be satisfied; one or more material agreements that may be entered into in connection with the Merger may be terminated by a party to the agreement; AgeX or the combined company may be unable to obtain approval to list on the NYSE American the shares of AgeX common stock expected to be issued pursuant to the Merger; and the closing of the Merger might be delayed or not occur at all. In addition, the Merger could cause AgeX to face additional risks, including risks associated with conducting and financing Serina’s current or future research and product development programs, including risks that those research and development programs will not result in the development of products or technologies with the desired clinical utility, benefits, or market acceptance; risks associated with conducting clinical trials of Serina product candidates and obtaining Food and Drug Administration or other regulatory approvals to market product candidates, including risks with respect to the timing of initiation of Serina’s planned clinical trials, the timing of the availability of data or other results from clinical trials, and the timing of any planned investigational new drug application or new drug application; risks associated with the combined company’s ability to identify additional products or product candidates with significant commercial potential; risks associated with AgeX’s, Serina’s or the combined company’s ability to protect its intellectual property position; product liability risks; the risk that the cash balance of the combined company following the closing of the Merger will be lower than expected or reduced; the risk that the combined company’s anticipated sources and related timing of financing following the closing of the Merger will not provide proceeds necessary to fund the operations of the combined company for as long as anticipated; the risk that the transactions contemplated by the Side Letter entered into by AgeX, Serina and Juvenescence on August 29, 2023 are not completed in a timely manner or at all; risks associated with AgeX’s or Serina’s estimates regarding future revenue, expenses, capital requirements, and need for additional financing following the Merger; risks associated with the ability of AgeX and the combined company to remain listed on the NYSE American; the risk that products may not be successfully commercialized or that the combined company might not otherwise be able to generate sufficient revenues to operate at a profit; potential adverse changes to business or employee relationships, including those resulting from the announcement or completion of the Merger; the risk that changes in AgeX’s capital structure, management, business, and governance following the Merger could have adverse effects on the market value of its common stock; the ability of AgeX and Serina to retain customers and retain and hire key personnel and maintain relationships with their suppliers and customers; risks associated with Serina’s or the combined company’s ability to successfully collaborate with Serina’s existing collaborators or enter into new collaborations, or to fulfill its obligations under any such collaboration agreements; risks associated with the combined company’s commercialization, marketing and manufacturing capabilities and strategy; the risk that pursuing and completing the Merger and related transactions could distract AgeX and Serina management from their respective ongoing business operations or cause AgeX and Serina to incur substantial costs; risks associated with competition and developments in the industry in which the combined company will operate; the impact of world health events and any related economic downturn; the risk of changes in governmental regulations or enforcement practices; AgeX’s and Serina’s ability to meet guidance, market expectations, and internal projections; the impact of AgeX stockholders having their percentage ownership interests in AgeX reduced by the issuance of AgeX common stock to Serina stockholders in the Merger and by the issuance of shares of AgeX common stock upon the exercise of Post-Merger Warrants by Juvenescence, and other important factors that could cause actual results to differ materially from those projected or expected by AgeX management or stockholders. The effects of many of such factors are difficult to predict and may be beyond AgeX’s or Serina’s control.

New factors emerge from time to time, and it is not possible for us to predict all such factors, nor can we assess the impact of each such factor on the business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Additional factors that could cause actual results to differ materially from the results anticipated in these forward-looking statements are contained in the Proxy Statement/Prospectus/Information Statement and AgeX’s periodic reports filed with the SEC under the heading “Risk Factors” and other filings that AgeX may make with the SEC. Forward-looking statements included in this communication are based on information available to AgeX and Serina as of the date of this communication. Undue reliance should not be placed on these forward-looking statements that speak only as of the date they are made, and except as required by law, AgeX and Serina each disclaims any intent or obligation to update these forward-looking statements.

Additional Information and Where to Find It

In connection with the proposed business combination transaction between AgeX and Serina, AgeX filed a registration statement on Form S-4/S-1 (the “Form S-4/S-1”) with the SEC that contains the Proxy Statement/Prospectus/Information Statement and other relevant documents concerning the proposed transaction. AGEX URGES INVESTORS AND STOCKHOLDERS TO READ THESE MATERIALS AND ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY CONTAIN AND WILL CONTAIN IMPORTANT INFORMATION ABOUT AGEX, SERINA AND THE PROPOSED TRANSACTION AND RELATED MATTERS. The Proxy Statement/Prospectus/Information Statement was first mailed to AgeX stockholders on or about February 20, 2024. Investors and stockholders will be able to obtain free copies of the Form S-4/S-1 and other documents filed by AgeX with the SEC (when they become available) through the website maintained by the SEC at www.sec.gov. In addition, investors and stockholders will be able to obtain free copies of the Form S-4/S-1 and other documents filed by AgeX with the SEC by contacting Andrea Park by email at apark@agexinc.com. Investors and stockholders are urged to read the Form S-4/S-1, including the Proxy Statement/Prospectus/Information Statement contained therein, and the other relevant materials when they become available before making any voting or investment decision with respect to the proposed transaction.

Participants in the Solicitation

AgeX and Serina, and each of their respective directors and executive officers and certain of their other members of management and employees, may be deemed to be participants in the solicitation of proxies in connection with the proposed transaction. Information about AgeX’s directors and executive officers is included in AgeX’s Annual Report on Form 10-K for the year ended December 31, 2022, filed with the SEC on March 31, 2023, in the proxy statement for AgeX’s 2023 annual meeting of stockholders, filed with the SEC on November 7, 2023, as supplemented by the supplement to the proxy statement for AgeX’s 2023 annual meeting of stockholders, filed with the SEC on November 14, 2023, and in AgeX’s Quarterly Report on Form 10-Q for the three and nine months ended September 30, 2023, filed with the SEC on November 14, 2023. Additional information regarding these persons and their interests in the transaction are included in the Proxy Statement/Prospectus/Information Statement. These documents can be obtained free of charge from the sources indicated above.

No Offer or Solicitation

This communication relates to a proposed business combination transaction between AgeX and Serina. This communication is for informational purposes only and does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval, in any jurisdiction, pursuant to the proposed business combination transaction or otherwise, nor shall there be any sale, issuance, exchange or transfer of the securities referred to in this communication in any jurisdiction in contravention of applicable law. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	AGEX THERAPEUTICS, INC.

Date: March 7, 2024	By:	/s/ Andrea E. Park
		Chief Financial Officer

EX-101.SCH 2 age-20240305.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 3 age-20240305_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 4 age-20240305_pre.xml XBRL PRESENTATION FILE XML 5 R1.htm IDEA: XBRL DOCUMENT

Cover	Mar. 05, 2024
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Mar. 05, 2024
Entity File Number	1-38519
Entity Registrant Name	AgeX Therapeutics, Inc.
Entity Central Index Key	0001708599
Entity Tax Identification Number	82-1436829
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	1101 Marina Village Parkway
Entity Address, Address Line Two	Suite 201
Entity Address, City or Town	Alameda
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94501
City Area Code	(510)
Local Phone Number	671-8370
Written Communications	true
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Trading Symbol	AGE
Security Exchange Name	NYSEAMER
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	true

EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.0.1 html 1 24 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://agexinc.com/role/Cover Cover Cover 1 false false All Reports Book All Reports age-20240305.xsd age-20240305_lab.xml age-20240305_pre.xml form8-k.htm http://xbrl.sec.gov/dei/2023 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "form8-k.htm": { "nsprefix": "AGE", "nsuri": "http://agexinc.com/20240305", "dts": { "schema": { "local": [ "age-20240305.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "age-20240305_lab.xml" ] }, "presentationLink": { "local": [ "age-20240305_pre.xml" ] }, "inline": { "local": [ "form8-k.htm" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "report": { "R1": { "role": "http://agexinc.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-03-05", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-03-05", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://agexinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://agexinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://agexinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://agexinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://agexinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://agexinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://agexinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://agexinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://agexinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://agexinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://agexinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://agexinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://agexinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://agexinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://agexinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://agexinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://agexinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://agexinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://agexinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://agexinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://agexinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://agexinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://agexinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://agexinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://agexinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://agexinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://agexinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://agexinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://agexinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://agexinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://agexinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://agexinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://agexinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://agexinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://agexinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://agexinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://agexinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://agexinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://agexinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://agexinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://agexinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://agexinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://agexinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://agexinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://agexinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://agexinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://agexinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://agexinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://agexinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://agexinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://agexinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://agexinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://agexinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://agexinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://agexinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://agexinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://agexinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://agexinc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 14 0001493152-24-009224-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-24-009224-xbrl.zip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form8-k_htm.xml IDEA: XBRL DOCUMENT 0001708599 2024-03-05 2024-03-05 iso4217:USD shares iso4217:USD shares false 0001708599 8-K 2024-03-05 AgeX Therapeutics, Inc. DE 1-38519 82-1436829 1101 Marina Village Parkway Suite 201 Alameda CA 94501 (510) 671-8370 Common Stock, par value $0.0001 per share AGE NYSEAMER true false false false true true